1266 The gut microbiome enhances anti-PD-1 efficacy in a tumor-agnostic manner: results from a phase II trial of fecal microbiota transplantation and anti-PD-1 re-induction in MSI-H refractory cancers

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Biology

Bioinformatics

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1136/jitc-2024-sitc2024.1266

License

CC-BY-NC

Other Formats

PDF